In the context of oncogenic signaling, the reciprocal activation between RUNX2 and the PI3K/AKT pathway has been recognized as a pivotal factor in driving tumor progression and fostering chemoresistance in osteosarcoma. The gene discussed is RUNX2; the disease is neoplasm.